Compounds > n-(2,5-bis(trifluoromethyl)phenyl)-5-bromo-2-hydroxybenzamide
Page last updated: 2024-11-12

n-(2,5-bis(trifluoromethyl)phenyl)-5-bromo-2-hydroxybenzamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11464503
SCHEMBL ID331595
MeSH IDM0489256

Synonyms (14)

Synonym
SCHEMBL331595
439144-66-8
benzamide, n-(2,5-bis(trifluoromethyl)phenyl)-5-bromo-2-hydroxy-
unii-419x829330
419x829330 ,
imd-0560
5-bromo-2-hydroxy-n-[2,5-bis(trifluoromethyl)phenyl]benzamide
n-[2,5-bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide
HY-105661
CS-7933
n-(2,5-bis(trifluoromethyl)phenyl)-5-bromo-2-hydroxybenzamide
Q27258424
MS-27565
AKOS040741873
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.75 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Ache
[description not available]		02.0810
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		02.0810
Bone Cancer
[description not available]		02.110
Carcinoma, Epidermoid
[description not available]		03.4320
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.9140
Cancer of Mouth
[description not available]		02.110
Metastase
[description not available]		02.110
Invasiveness, Neoplasm
[description not available]		03.4320
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.110
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		03.4320
Mouth Neoplasms
Tumors or cancer of the MOUTH.		02.110
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.110
Preterm Birth
[description not available]		02.1310
Amnionitis
[description not available]		02.1310
Innate Inflammatory Response
[description not available]		02.1310
Chorioamnionitis
INFLAMMATION of the placental membranes (CHORION; AMNION) and connected tissues such as fetal BLOOD VESSELS and UMBILICAL CORD. It is often associated with intrauterine ascending infections during PREGNANCY.		02.1310
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1310
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.1310
Premature Birth
CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).		02.1310
Cancer of Jaw
[description not available]		03.0410
Cancer of Ovary
[description not available]		02.1310
Peritoneal Carcinomatosis
[description not available]		02.1310
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.1310
Peritoneal Neoplasms
Tumors or cancer of the PERITONEUM.		02.1310
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0410
Cardiac Remodeling, Ventricular
[description not available]		02.0410
Cardiac Failure
[description not available]		02.0410
Cardiovascular Stroke
[description not available]		02.0410
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		02.0410
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		02.0410
Adjuvant Arthritis
[description not available]		02.0210
Rheumatoid Arthritis
[description not available]		02.0210
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.0210